Replies to post #620754 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

This raises questions about the terms of the CDMO contract service agreement. Advent retains a certain percentage of revenue given it’s a cost plus contract — that’s just obvious. (FeMike addresses some of this already.) But what’s defined as a cost and what the waterfall looks like for how revenue is allocated are really the important questions, including whether there’s a break even for number of patients treated under the specials program before revenue flows to NWBO’s financial statements.

Presumably as shareholders, we’re concerned about revenue to NWBO less so than how much profit Advent makes.

[hoffmann6383]

We simply don't know enough information to determine what is happening. Im guessing on what might be happening. The fudsters are guessing but instead of telling you they're guessing they are pretending like their guesses are fact and using an information vacuum to float the most negative narratives possible.

As far as using flaskworks to make DCVax-L, I don't think they can do that until the system is approved.